Frost & Sullivan releases theGlobal Gene Therapy Industry Development Blue Book for 2026'Frost & Sullivan' 'Frost & Sullivan China' 'LeadLeo' 'LeadLeo Research Institute' 'LeadLeo' 'YUAN CAPITAL' 'SULLIVAN TELE-TREND CLOUD TECHNOLOGY' 'TradeGo' 'MagnaTEC' 'Automotive & Mobility' 'Environmental Protection & Energy Saving Technology' 'Logistics & Supply Chain' 'MATERNAL AND INFANT' 'Education & Training' 'Real Estate & Property' 'Catering & New Retailing' 'Advanced Materials' 'Healthcare & Life Sciences' 'Semiconductor & Chip' 'COMMERCIAL AVIATION' 'Technology, Media and Telecom' 'LANDSCAPING' 'Big Data & AI' 'Infrastructure Construction & Utilities' 'Culture & Entertainment' 'AGRICULTURE, FORESTRY ANIMAL HUSBANDRY AND FISHERY' 'Food & Beverage' 'Fintech' 'SHIPPING AND PORTS' 'Dual Carbon & New Energy' 'Mining & Metals' 'Public Sector' 'Cross-Border E-commerce Trade' 'Building Technology, Construction & Decoration' 'Beauty & Fashion' 'Smart Homes' 'Digital Infrastructure' 'Enterprise Services' 'Consumer Electronics'
Frost & Sullivan releases the " Global Gene Therapy Industry Development Blue Book "
Frost & Sullivan’s '2026 Global Gene Therapy Industry Development Blue Book' aims to systematically examine the current status and future trends of the global gene therapy industry, driven by advancements in technological breakthroughs, regulatory improvements, capital investment, and commercial implementation. The Blue Book will analyze aspects such as the industry’s development history, core classifications, policy and capital dynamics, supply chains, viral vector production challenges, clinical progress in key applications, reimbursement methods, and competitive landscape, with a focus on identifying key challenges and opportunities in vector technologies, scale-up manufacturing, clinical translation, commercial reimbursement, and regulatory frameworks. By connecting industry participants, investment institutions, and regulatory entities, the Blue Book provides forward-looking market insights and strategic guidance for corporate technology planning, product development, industrial decision-making, international cooperation, and standard improvement
Frost & Sullivan’s release of the 2026 Global Gene Therapy Industry Development Blue Book aims to systematically review the current state and future trends of the global gene therapy industry, driven by concurrent advances in technological breakthroughs, regulatory improvements, capital investment, and commercial rollout. The Blue Book will analyze the industry’s development history, core classifications, policy and capital dynamics, upstream and downstream supply chains, viral vector production bottlenecks, clinical progress in key indications, reimbursement pathways, and competitive landscape, with a particular focus on identifying critical challenges and opportunities in vector technologies, scale-up manufacturing, clinical translation, commercial reimbursement, and regulatory frameworks. By connecting industry chain players, investment institutions, and regulatory bodies, the Blue Book seeks to provide forward-looking market insights and strategic references for corporate technology planning, product development, industrialization decisions, international collaboration, and the refinement of industry standards
Click on the following link to view the summary version of the report:
If you have further research needs regarding the 'Global Gene Therapy Industry Development Blue Book', please contact us:
Mr. Mao Fred
E-mail: fred.mao@frost.com
